Part 1 of the MATINS Phase I/II Study Completed
Faron Pharmaceuticals Oy ("Faron" or the "Company") Completion of Part 1 dose finding stage of the MATINS Phase I/II Study Study data monitoring committee recommends rapid expansion of study into new tumour types following promising results Company announcement, 30 March 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces positive feedback from the MATINS study data monitoring committee ("DMC") following a comprehensive review